

## News and Deals

### 1. Angle Health: \$200M Series C within a \$600M equity financing | Sep. 18, 2026

Angle Health announced a \$600M equity financing at a \$2.7B valuation, comprising a \$200M Series C and a \$400M tender offer. Vitruvian Partners led the round, with Town Hall Ventures and existing investors participating, as the AI-native health benefits platform expands beyond the 5,000 employers it serves.

**HDIG take:** Health benefits: the scale of this financing underscores investor conviction that software-led plan design and administration can take share from traditional small-group insurance. [LINK](#); [LINK](#)

### 2. Sling Therapeutics: \$123M Series C for an oral thyroid eye disease therapy | Sep. 16, 2026

Sling Therapeutics closed a \$123M Series C led by Forbion, with TPG Life Sciences Innovations and Sectoral Asset Management participating. Proceeds support the global Phase 3 ORBIT trial of linsitinib, an oral IGF-1R inhibitor for moderate-to-severe active thyroid eye disease.

**HDIG take:** Late-stage biotech: capital is concentrating around differentiated delivery and convenience advantages when a validated target can support a shorter path to commercialization. [LINK](#); [LINK](#)

### 3. Thatch: \$108M Series C for consumer-directed employer health benefits | Sep. 15, 2026

Thatch raised a \$108M Series C at a \$1B valuation from The General Partnership, Index Ventures, Scale Venture Partners, General Catalyst and Andreessen Horowitz, with strategic participation from Eli Lilly and Paychex. The company provides infrastructure for employers to offer individualized health reimbursement arrangements.

**HDIG take:** Benefits technology: ICHRA infrastructure is maturing into a scaled distribution layer as employers seek more predictable costs and employees gain more plan choice. [LINK](#); [LINK](#)

### 4. RegCell: \$44M Series A plus a \$22M grant for autoimmune cell therapy | Sep. 15, 2026

RegCell secured a \$44M Series A led by Playground Global and a second AMED grant of approximately \$22M. The combined financing will support an FDA IND submission and advance an epigenetically reprogrammed regulatory T-cell platform into a second autoimmune indication.

**HDIG take:** Cell therapy: the program pairs high-conviction immune-tolerance biology with non-dilutive funding, helping absorb manufacturing and translational risk before clinical proof of concept. [LINK](#); [LINK](#)

### 5. Evvy: \$40M Series B for vaginal microbiome diagnostics and care | Sep. 15, 2026

Evvy raised a \$40M Series B led by Catalio Capital Management, with participation from General Catalyst, Rethink Impact, LabCorp Venture Fund and others. The women's health company combines at-home metagenomic testing, clinician review and personalized treatment pathways built around vaginal microbiome data.

**HDIG take:** Women's health: the round validates a diagnostics-plus-care model that turns longitudinal microbiome data into a defensible clinical and research asset. [LINK](#); [LINK](#)

## 6. ReEmerge: \$37M Series A for chronic cognitive impairment treatment | Sep. 15, 2026

ReEmerge launched from stealth with an oversubscribed \$37M Series A to advance Cognitive Network Restoration Therapy. The financing will support a first clinical study in chronic cognitive impairment after traumatic brain injury, plus technology, regulatory and clinical operations.

**HDIG take:** Neurotechnology: the company is targeting durable restoration rather than compensatory rehabilitation, creating a high-upside but clinically demanding medtech thesis. [LINK](#); [LINK](#)

## 7. Altis Labs: \$25M Series A for AI endpoints in oncology trials | Sep. 17, 2026

Altis Labs closed a \$25M Series A co-led by OrbiMed and Qiming Venture Partners USA, with Innovation Endeavors, Benchstrength, Fusion Fund and the Cancer Breakthrough Fund participating. The company will expand AI imaging endpoints across cancer types and scale deployment with biopharma partners.

**HDIG take:** Clinical development AI: outcome-linked imaging models could shorten efficacy readouts and improve go/no-go decisions in oncology, where trial delays carry outsized cost. [LINK](#); [LINK](#)

## 8. Piomic Medical: \$25M growth financing for a wound-care device | Sep. 18, 2026

Piomic Medical closed a \$25M growth financing led by Swisscanto, with existing investors participating. Funding will complete clinical development, support the FDA market-approval process and prepare U.S. launch of the COMS One therapy system for hard-to-heal wounds.

**HDIG take:** Medtech: regulatory, clinical and reimbursement work are advancing together, reducing the commercialization gap that often slows novel wound-care technologies. [LINK](#); [LINK](#)

## 9. Polyphron: \$20M Seed for AI-guided human tissue models | Sep. 17, 2026

Polyphron raised a \$20M Seed round from Compound, Gradient Ventures, Haystack and Quiet Capital. The company is building AI-guided, donor-diverse human tissue models intended to provide a physical verification layer for drug discovery predictions and tissue manufacturing.

**HDIG take:** Drug R&D infrastructure: better human-relevant validation could become a critical complement to generative biology as therapeutic hypotheses outpace experimental throughput. [LINK](#); [LINK](#)

## 10. Ayble Health: \$16M Series A for AI-enabled digestive and autoimmune care | Sep. 16, 2026

Ayble Health closed an oversubscribed \$16M Series A led by Neon, with Unum Ventures, Upfront Ventures, M13, Cleveland Clinic Ventures, DigiTx and Accomplix participating. The company will expand its AI-plus-clinician digestive care model into adjacent autoimmune conditions.

**HDIG take:** Virtual specialty care: evidence-backed multidisciplinary models are attracting capital where they can demonstrate both clinical improvement and lower avoidable utilization. [LINK](#); [LINK](#)

## 11. Nix Biosensors: \$10M Series A for hydration intelligence | Sep. 15, 2026

Nix Biosensors closed a \$10M Series A, bringing total funding to \$17M, with Shorewind Capital, Great Oaks Venture Capital, White Road Investments and strategic individuals participating. The company is extending its sweat-sensing dataset into licensable hydration algorithms for consumer health platforms.

**HDIG take:** Wearables: moving from proprietary hardware toward embedded algorithms can broaden distribution while preserving the value of a differentiated physiological dataset. [LINK](#); [LINK](#)

## 12. Ferry Health: \$9M Seed for an AI healthcare personal assistant | Sep. 16, 2026

Ferry Health launched from stealth with \$9M in Seed funding from Andreessen Horowitz, Index Ventures, Avid Ventures, Layout Ventures, SV Angel, BoxGroup and Asymmetric Capital. Its AI assistant starts with provider search and appointment scheduling and is available through payer and care-platform partners.

**HDIG take:** Patient access: agentic navigation is moving closer to transaction execution, where integrations and completion rates matter more than conversational polish. [LINK](#); [LINK](#)

## Upcoming Healthcare Events

| Date             | Event                                                                 | Location         | Why it matters                                                                                                                                        |
|------------------|-----------------------------------------------------------------------|------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|
| Sep. 23-25, 2026 | <a href="#">HFMA Region 6 Conference</a> ,                            | Grand Rapids, MI | For Revenue Cycle and Finance professionals the Blueprints of Hope will focus on tactics and leadership in a more complicated and shifting landscape. |
| Sep. 29, 2026    | <a href="#">Becker's Webinar: From Evaluation to Enterprise Value</a> | Virtual          | Health-system leaders discuss how to select, measure and expand clinical AI from isolated deployments into enterprise infrastructure.                 |
| Oct. 1-2, 2026   | <a href="#">OMD Educates: Digital Health Conference 2026</a>          | Toronto, ON      | Clinician-focused program on EMRs, AI tools, privacy, connected care, practice optimization and start-up technologies.                                |
| Oct. 15, 2026    | <a href="#">Becker's Webinar: The Art of Quiet CDI</a>                | Virtual          | Health IT session on embedding clinical integrity and documentation guidance at the point of care without disruptive retrospective workflows.         |